Table 1 Efficacy of onabotulinumtoxinA 155 U.
From: P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine
| Â | baseline | 3 m | 6 m | 9 m | 12 m | 15 m | 18 m | 21 m | 24 m |
Headache days | 22.3 | -5.9 | -9.4 | -10.7 | -12.9 | -13.2 | -13.6 | -14.3 | -15 |
Migraine days | 21.4 | -5.6 | -8.4 | -9.5 | -12.3 | -13.1 | -13.5 | -14.1 | -14.6 |
Acute pain medication intake days | 20.8 | -6.6 | -9 | -9.8 | -12.1 | -12.6 | -13.2 | -14.8 | -15.6 |
HIT-6 score | 69.4 | -- | -5.1 | -- | -10.9 | -- | -14 | -- | -17.4 |